Löscher W, Hönack D
Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, F.R.G.
Eur J Pharmacol. 1989 Mar 21;162(2):309-22. doi: 10.1016/0014-2999(89)90294-x.
In amygdala-kindled rats, single-dose administration of primidone did not reduced seizure activity 2 h after i.p. injection, i.e. when plasma levels of the drug were highest, but significant anticonvulsant effects were found 24 h after administration, when the drug was almost completely eliminated. During chronic treatment with primidone, marked anticonvulsant efficacy was determined after 3-15 days of three times daily treatment with 50 mg/kg i.p., indicating that this effect was due to the accumulation of metabolites, especially phenobarbital. Maximum anticonvulsant activity attained during chronic primidone medication was almost equal to that found during chronic treatment of kindled rats with phenobarbital, 30 mg/kg once daily. However, drug plasma level determinations during both treatments showed that on days when both treatments were about equieffective, levels of metabolically derived phenobarbital in the primidone group were significantly lower than levels in rats treated with phenobarbital alone, thus indicating that primidone potentiated the anticonvulsant effect of metabolically derived phenobarbital. Additional evidence for potentiation of the anticonvulsant effect of phenobarbital by primidone was found in single dose experiments with combined injection of both drugs, whereas side-effects, such as ataxia and muscle relaxation, induced by phenobarbital were not increased by combined treatment with primidone. Accordingly, side-effects occurring during chronic primidone treatment were less pronounced than side-effects found during chronic phenobarbital medication. In both treatment groups, tolerance to the anticonvulsant effect developed during the 2nd week of administration, while attenuation of side-effects took place already in the first week. Following cessation of treatment, signs of physical dependence, such as withdrawal hyperexcitability and weight loss, were observed. The data indicate that, at least in kindled rats, the anticonvulsant activity of primidone during chronic treatment is due to the combined and possibly synergistic actions of primidone and metabolically derived phenobarbital.
在杏仁核点燃的大鼠中,腹腔注射一次剂量的扑米酮在2小时后(即药物血浆水平最高时)并未降低癫痫发作活动,但在给药24小时后发现了显著的抗惊厥作用,此时药物几乎已完全消除。在扑米酮的慢性治疗期间,每天腹腔注射50mg/kg、连续治疗3 - 15天后,确定了显著的抗惊厥疗效,这表明这种作用是由于代谢产物尤其是苯巴比妥的积累。慢性扑米酮用药期间达到的最大抗惊厥活性几乎与每天一次腹腔注射30mg/kg苯巴比妥对点燃大鼠进行慢性治疗时所发现的活性相当。然而,两种治疗期间的药物血浆水平测定表明,在两种治疗效果大致相当的日子里,扑米酮组中代谢产生的苯巴比妥水平显著低于单独用苯巴比妥治疗的大鼠中的水平,因此表明扑米酮增强了代谢产生的苯巴比妥的抗惊厥作用。在两种药物联合注射的单剂量实验中发现了扑米酮增强苯巴比妥抗惊厥作用的额外证据,而扑米酮联合治疗并未增加苯巴比妥诱导的共济失调和肌肉松弛等副作用。因此,慢性扑米酮治疗期间出现的副作用比慢性苯巴比妥用药期间发现的副作用要轻。在两个治疗组中,给药第2周期间对抗惊厥作用产生了耐受性,而副作用的减轻在第1周就已出现。停止治疗后,观察到了身体依赖性的迹象,如戒断性过度兴奋和体重减轻。数据表明,至少在点燃大鼠中,慢性治疗期间扑米酮的抗惊厥活性是由于扑米酮和代谢产生的苯巴比妥的联合作用以及可能的协同作用。